Total Valuation
GlaxoSmithKline has a market cap or net worth of CHF84.36B. The enterprise value is CHF95.13K.
Market CapCHF84.36B
Enterprise ValueCHF95.13K
Share Statistics
GlaxoSmithKline has 4,045,395,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,045,395,300
Owned by Insiders1.14%
Owned by Institutions0.07%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 14.25%.
Return on Equity (ROE)0.35
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)14.25%
Return on Capital Employed (ROCE)0.18
Revenue Per Employee488.73K
Profits Per Employee85.52K
Employee Count66,841
Asset Turnover0.53
Inventory Turnover1.51
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 16.1. GlaxoSmithKline’s PEG ratio is 0.10.
PE Ratio16.1
PS Ratio2.26
PB Ratio4.51
Price to Fair Value4.51
Price to FCF12.41
Price to Operating Cash Flow9.61
PEG Ratio0.10
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 1.41.
Revenue32.67B
Gross Profit23.70B
Operating Income7.17B
Pretax Income7.40B
Net Income5.72B
EBITDA11.88B
Earnings Per Share (EPS)1.41
Cash Flow
In the last 12 months, operating cash flow was 7.98B and capital expenditures -2.22B, giving a free cash flow of 5.76B billion.
Operating Cash Flow7.98B
Free Cash Flow5.76B
Free Cash Flow per Share1.42
Dividends & Yields
GlaxoSmithKline pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change0.00%
50-Day Moving Average26.12
200-Day Moving Average26.11
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
GlaxoSmithKline upcoming earnings date is Oct 28, 2026, Before Open (Confirmed).
Last Earnings DateJul 28, 2026
Next Earnings DateOct 28, 2026
Ex-Dividend Date―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 103.36%
Current Ratio0.82
Quick Ratio0.54
Debt to Market Cap0.23
Net Debt to EBITDA1.23
Interest Coverage Ratio10.23
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
Income Tax1.11B
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 7.45, with an EV/FCF ratio of 14.86.
EV to Sales2.71
EV to EBITDA7.45
EV to Free Cash Flow14.86
EV to Operating Cash Flow12.12
Balance Sheet
GlaxoSmithKline has CHF3.11B in cash and marketable securities with CHF18.24B in debt, giving a net cash position of -CHF15.13B billion.
Cash & Marketable SecuritiesCHF3.11B
Total DebtCHF18.24B
Net Cash-CHF15.13B
Net Cash Per Share-CHF3.74
Tangible Book Value Per Share-CHF1.93
Margins
Gross margin is 73.29%, with operating margin of 21.95%, and net profit margin of 17.50%.
Gross Margin73.29%
Operating Margin21.95%
Pretax Margin22.66%
Net Profit Margin17.50%
EBITDA Margin36.38%
EBIT Margin24.81%
Analyst Forecast
The average price target for GlaxoSmithKline is CHF23.23, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetCHF23.23
Price Target Upside-11.05% Downside
Analyst ConsensusHold
Analyst Count15
Revenue Growth Forecast-0.33%
EPS Growth Forecast35.94%